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Abstract
Cisplatin (CDDP) is an effective anticancer agent for many solid tumors but has significant
systemic toxicity limiting its use in many patients. We have designed a loco-regional delivery
system to increase platinum levels in the lymphatics, where early metastasis is most likely to
occur, while reducing systemic toxicities. CDDP was conjugated to a biocompatible polymer
hyaluronan (HA), with a conjugation degree of approximately 20% (w/w). Conjugates were
delivered via subcutaneous injection into the mammary fat pad of rats. Intravenous hyaluronan–
cisplatin (HA–Pt) exhibited an increased plasma area under the curve (AUC) 2.7-fold compared to
conventional CDDP but with a reduced peak plasma level (Cmax), and HA–Pt increased the
ipsilateral lymph node AUC by 3.8-fold compared to CDDP. Urine creatinine was unchanged over
30 days following dosing of HA–Pt. This study demonstrates that intralymphatic drug delivery
with polymer-conjugated platinum may provide greater tissue and systemic plasma concentrations
of platinum than intravenous CDDP. In addition, localized particle delivery augmented
distribution in the loco-regional tissue basin where tumor burden predominates, while renal
toxicity compared to standard intravenous CDDP was significantly reduced.
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Introduction
Since the FDA's approval of CDDP in 1977 for the treatment of metastatic ovarian cancer,1
CDDP has emerged as the principal chemotherapeutic agent for many solid tumors, despite
newer platinum drugs with fewer side effects. CDDP has a high initial response rate in many
cancers including head and neck squamous sarcomas, lymphomas, small cell and nonsmall
cell lung, testicular, ovarian, gastric, esophagus, and pancreatic cancers.2 Although not
clinically employed as a single agent, CDDP is highly active in combination with
chemotherapeutic regimens for breast cancer,3 but the significant dose-limiting toxicity of
CDDP has hampered its use in many patients.
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Nephrotoxicity is the most dangerous and insidious of CDDP's side effects, as exhibited by
renal tubular inflammation and necrosis.4 After administration, CDDP binds tightly to
plasma proteins and becomes highly concentrated compared to the plasma or other organs in
the kidneys and free CDDP is filtered.5 CDDP efficacy is well correlated with AUC but not
with maximum plasma concentration (Cmax);6 however, toxicity is increased by high peak
drug concentrations, such as immediately after bolus injection or during short i.v. infusions,
further increasing the risk of nephrotoxicity.2 Fractional or metronomic dosing schedules
that divide the same total dose of CDDP over several, for example, daily, smaller injections,
have been shown to significantly reduce nephrotoxicity and ototoxicity6,7 due to lower peak
plasma concentration. However, metronomic dosing requires a more frequent dosing
schedule, longer in-hospital stays, and leads to increased care costs thereby limiting its use.
Since nonspecific organ toxicities hamper CDDP chemotherapy, oncologists have developed
procedures to confine chemotherapy to the diseased areas by temporarily isolating the
affected tissues or organs from the systemic circulation and perfusing them with CDDP. For
example, intraarterial percutaneous pelvic perfusion of high-dose CDDP has demonstrated a
therapeutic advantage in advanced uterine cervical carcinoma8 while achieving a low side-
effect profile. However, these treatments are highly invasive and require specialized skills
and equipment usually restricted to large medical research centers. In addition, tissue
isolation is not possible in many clinical cases, including locally advanced breast cancer that
has significant invasion into lymphatic tissues.
Treatment of locally advanced cancers may be improved if chemotherapy were concentrated
to the draining lymphatics, while maintaining adequate systemic levels for the treatment of
distant metastases. Previously we compared direct injection into rat breast tissue of CDDP
with a silver-activated conjugate of CDDP;9 however, local injection of CDDP is not
clinically feasible due to extensive tissue damage. Furthermore, tumor studies demonstrated
that the silver activated conjugate to cause premature animal death, which promoted our
development of a new conjugate that does not require silver. In this report, we examine a
conjugate of the polysaccharide HA with CDDP that can concentrate CDDP to the
lymphatics and reduce peak plasma concentrations. Localized conjugate chemotherapy
significantly increases lymphatic tissue concentrations over systemic therapy and reduces
organ toxicities including nephrotoxicity in rats.
Materials and Methods
HA from microbial fermentation was purchased from Lifecore Biomedical (Chaska, MN) as
sodium hyaluronate and used without further purification. Heparin solution was purchased
from Abraxis Pharmaceutical Products (Schaumburg, IL). All other reagents were purchased
from Fisher Scientific (Pittsburgh, PA) or Sigma–Aldrich (St. Louis, MO) and were of ACS
grade or better. Milli-Q water was used in all experiments. Animal procedures were
approved by the University of Kansas Institutional Animal Care and Use Committee.
Sprague–Dawley rats were purchased from Charles River Laboratories (Wilmington, MA).
Cell lines were obtained from American Tissue Culture Collection (ATCC, Manassas, VA)
and cultured according to the provided protocols unless noted otherwise. Caution: CDDP is
extremely toxic and all chemical waste and animal tissues were treated as hazardous waste
and disposed of accordingly.
Synthesis and Characterization of Hyaluronan–CDDP (HA–Pt) Conjugates
CDDP was conjugated to HA (35,000 g/mol) based on previously reported procedures,9,10
with and without the addition of silver nitrate as an activating agent. Typically, HA (100
mg) and CDDP (45 mg) were dissolved in H2O (20 mL) and stirred in the dark for 4 days
under argon at ambient temperature (ca. 25°C). The reaction mixture was filtered (0.2-μm
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nylon membrane) and dialyzed against H2O (10,000 MWCO; Pierce, Rockford, IL) for 48 h
at 4°C protected from light. Following dialysis, the crude product was concentrated and
stored at 4°C. The degree of CDDP substitution was determined by atomic absorption
spectroscopy (AAS) (Varian SpectrAA GTA-110 with graphite furnace). The furnace
program was as follows: ramp to 25–80°C, hold 2 s, ramp to 120°C, hold 10 s, ramp to
1000°C, hold 5 s, ramp to 2700°C, hold 2 s, cool to 25°C over 20 s. The graphite partition
tube was cleaned in every 40 samples by baking at 2800°C for 7 s. Argon was used as the
injection and carrier gas.
The size of the HA–Pt conjugate was determined by field emission transmission electron
microscopy (FEI, Hillsboro, OR). A concentrated solution of the HA–Pt conjugates was
coated on a lacey carbon-coated copper grid (Ted Pella, Inc., Redding, CA) before imaging.
Diameters were determined using ImageJ (National Institutes of Health,
http://rsbweb.nih.gov/ij/) for Fert's sizing analysis (n = 40 particles).
The in vitro release rate of the active hydrated form of the cisplatin (cis-[Pt(NH3)2
(H2O)2]+) from the HA– Pt conjugate was determined in both water and phosphate-buffered
saline (PBS, pH 7.4, 140 mM NaCl) solution. HA–Pt was added to a 10,000 MWCO
dialysis bag (Pierce) and placed in a water or PBS bath and stirred at 37°C. The bath volume
(3 L) was replaced every 4 h to maintain sink conditions. Samples were taken from the
dialysis bag at predetermined time points, and the remaining Pt concentration was
determined by AAS.
The lymphatically metastatic breast cancer cell line MDA-MB-468LN, kindly provided by
Ann Chambers of the London Health Sciences Center, was maintained in modified Eagle's
medium alpha supplemented with 10% fetal bovine serum, 1% L-glutamine, and 0.4 mg/mL
G418 (geneticin).9,11 Additional cell lines MDA-MB-231, MCF-7, JMAR, and MDA-1986
were maintained in DMEM with 10% fetal bovine serum and 1% penicillin/streptomycin.
Preceding proliferation studies, cells were trypsinized and seeded into 96-well plates (5000
cells/well). After 24 h, CDDP, HA–Pt, or HA was added (n = 12; seven concentrations), and
72 h postaddition, resazurin blue in 10 μL of PBS was added to each well (final
concentration of 5 μM). After 4 h, well fluorescence was measured (λex 560 nm, λem 590
nm) using a fluorophotometer (SpectraMax Gemini; Molecular Devices, Sunnyvale, CA).
IC50 was determined as the midpoint between saline (positive) and cell-free (negative)
controls for each plate. Each experiment was repeated in triplicate.
Pharmacokinetics and Tissue Distribution
Sprague–Dawley rats (female, 200–250 g) were cannulated in the left jugular vein under
isoflurane and allowed to recover overnight. Animals were then administered i.v. CDDP, i.v.
HA–Pt, s.c. HA–Pt, or s.c. CDDP (1.0 or 3.3 mg/kg equivalent CDDP; n = 5 for each group)
under isoflurane anesthesia. Subcutaneous injections were given in the uppermost right
mammary fat pad of the animal. Whole blood was withdrawn (100 μL) from the cannula at
0, 5 min, 0.5 h, 1 h, 2 h, 4 h, 6 h, 12 h, 24 h, 48 h, and 96 h after dosing and placed into 2-
mL centrifuge tubes pretreated with heparin. The cannula was washed before and after
withdrawal with saline and then heparin locked. The whole blood was centrifuged at
17,000×g for 5 min, and the plasma was frozen at −80°C until analysis. In tissue distribution
studies, age and weight matched animals were administered the drugs and euthanized at the
stated time points. The right ipsilateral axilla nodes (treated side), left contralateral axilla
nodes (control side), and major organs (liver, kidneys, heart, spleen, lungs, brain, muscle,
bladder) were excised; washed with 0.9% saline; and stored at −80°C until analysis. Tissue
samples were prepared using a procedure reported previously.9 Typically, 50 mg of tissue
sample was digested using 1.5 mL of 6.7% nitric acid for 2 h at 80°C. After digestion,
samples were homogenized (Tissue Tearor; BioSpec Products, Inc., Bartlesville, OK) and
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centrifuged. The supernatant and plasma samples were analyzed by AAS as described in the
Synthesis and Characterization of Hyaluronan– CDDP (HA–Pt) Conjugates.
Toxicology Analysis
Sprague–Dawley rats (35 females) were randomly divided into study groups of five animals
each and dosed: 1.0 mg/kg s.c. HA–Pt (with and without silver; platinum equivalent to 1.0
mg/kg CDDP), 3.3 mg/kg s.c. HA–Pt (with and without silver), i.v. CDDP at 1.0 and 3.3
mg/kg s.c.. HA (control; HA equivalent to 3.3 mg/kg HA–Pt). Each animal was
administered a single bolus dose at the beginning of the 30-day study period. Urine samples
were collected every day during the first 2 weeks of the study and every 4 days during the
third and fourth week of the studies (except for the 3.3 mg/kg HA–Pt with silver group). In
order to reduce the morbidity to animals, subjects were housed in metabolic cages for 12 h
to collect approximately 5 mL of urine and then returned to cages with bedding until the
next collection period. Urine samples were centrifuged at 17,000g for 5 min and stored in
−80°C freezer until creatinine analysis.
Creatinine Analysis—Urine creatinine was analyzed using the Quanti-Chrom™
Creatinine Assay Kit according to the manufacturer's instructions (BioAssay Systems,
Hayward, CA). Creatinine concentration of the sample was calculated as (ODSAMPLE 5 −
ODSAMPLE 1)/(ODSTD 5 − ODSTD 1) × [STD] (mg/dL). ODSAMPLE 5, ODSAMPLE 1,
ODSTD 5, and ODSTD 1 are OD510 nm values of sample and standard at 5 and 1 min,
respectively. [STD] is 50 mg/dL for the urine assay.
Results
Synthesis and Analysis of HA–Pt Conjugates
The structure of CDDP lends itself to complex formation with polycarboxylic polymers,
since one or more of the chlorides can be displaced allowing formation of a labile ester
linkage with the polymer.12 CDDP was highly conjugated to HA with typical conjugations
of 0.20 (w/w) platinum/complex (approximately 65% CDDP conjugation efficiency). In
previous studies, we synthesized CDDP conjugates by first activating HA with AgNO3, but
we found eliminating this step does not significantly reduce conjugation and eliminates
potential silver toxicity. The AAS produced a linear curve in the range of 10– 450 ng/mL
(R2 = 0.999) with a limit of detection of 5 ng/mL. Concentrated samples were diluted with
0.1% nitric acid into the linear analytical range prior to analysis.
The HA–Pt conjugates formed individual particles of approximately 7.55 ± 1.72 nm (n = 40
particles), with some larger clusters (ca. 25.20 ± 4.43 nm, n ± 40 groups) of conjugates.
Clustering was likely due to the formation of alternating hydrophobic regions created by the
eight adjacent CH groups that are present for every three disaccharides (Fig. 1). Overall, the
formed particles were within the scopic size range shown to have good lymphatic uptake
and nodal retention.13
The in vitro release of platinum from the complexes exhibited pseudo-first-order release
kinetics with a release half-life of 42 h in water and 10 h in PBS (Fig. 2). The release rate
constant was determined to be 0.0148 s−1 in water and 0.0700 s−1 in PBS, respectively. The
chloride ion in PBS was expected to more rapidly displace the carboxylate group bound to
the platinum, increasing the release rate of the hydrated platinum.
Cell toxicity was determined as the reduction in cell proliferation over 72 h. No appreciable
difference in toxicity was detected between CDDP and HA–Pt in three human breast cancer
cell lines and two head and neck squamous cell carcinoma lines (Tab. 1). HA showed no
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toxicity at 10 mg/mL, the upper limit of testing in all cell lines compared with saline
controls (data not shown).
Pharmacokinetics and Tissue Distribution
The pharmacokinetic parameters of HA–Pt and CDDP were determined by fitting individual
animals' data to a two-compartment model with SAAM II (version 1.2, University of
Washington; Tab. 2). The AUC of s.c. HA–Pt was 660% greater than i.v. CDDP. The
plasma half life (t1/2) of s.c. HA–Pt was 200% greater than i.v. CDDP and 490% greater
than i.v. HA–Pt. Clearance rates (Cl) of s.c. HA–Pt and i.v. HA–Pt were not significantly
different, but the total body clearance (Cl) of i.v. CDDP was 590% greater than s.c. HA–Pt.
The steady-state volume of distribution (Vss) of platinum was greater for the i.v. CDDP than
s.c. or i.v. HA–Pt.
The s.c. HA–Pt preferentially accumulated in the draining ipsilateral axillary lymph nodes as
compared to the i.v. CDDP control (Fig. 3); preferential accumulation was still evident at 48
h postinjection despite an in vitro disassociation half-life of Pt from HA of 10 h.9 The
ipsilateral axillary node AUC of HA–Pt when injected locally was 279% greater than i.v.
CDDP node levels (p < 0.001), and the peak node concentration (Cmax) of HA–Pt was 520%
greater than i.v. CDDP. The relative organ AUCs for i.v. CDDP were kidneys > axilla nodes
> spleen > liver > bladder > brain > muscle > lungs > heart; for s.c. HA–Pt, ipsilateral axilla
nodes > kidneys > liver > heart > contralateral axilla nodes > spleen > lungs > brain >
muscle > bladder. The ratio of tissue AUCs to plasma AUCs (i.e., tissue clearance) for i.v.
CDDP were kidneys > axilla nodes > spleen > liver > brain > bladder > muscle > lungs >
heart; for s.c. HA–Pt, ipsilateral axilla nodes > kidneys > liver > heart > contralateral axilla
nodes > spleen > lungs > brain > muscle > bladder. CDDP was injected s.c. as a comparison
to the carrier HA–Pt. There was no apparent increase in concentration in the draining lymph
nodes, but the muscle tissue near the injection site had the highest platinum concentrate
relative to the other tissues.
Toxicology
Urine creatinine levels are an indirect indicator of glomerular filtration rate which can
indicate changes in renal function and renal toxicity. A decrease in creatinine excretion
corresponds to a decreased renal function and possible renal toxicity or damage. Significant
renal toxicity was observed in animals administered our initial HA–Pt silver conjugate (3.3
mg/kg), with a 30% decrease in creatinine excretion apparent at 3 days and a 70% decrease
at 4 days (Fig. 4). All animals in this group died within 1 week of treatment due to drug-
related cachexia. In contrast, the HA–Pt did not demonstrate significant toxicity, and
creatinine levels remained near predosing levels throughout the study's duration. Toxicity as
measured by creatinine excretion was compared to our previous silver formulation, which
had not been previously assessed. The silver-free formulations reported here demonstrate
significantly less renal toxicity. The higher levels of platinum in neural tissues may
potentiate toxicity, brain sections of the treated animals were preserved in 80% alcoholic
formalin solution, stained with hematoxylin and eosin, and then examined and graded by an
independent blinded veterinarian pathologist (Veterinary Lab Resources; University of
Kansas Medical Center). The brain tissues of the CDDP and HA–Pt treated groups had no
microscopic lesions or abnormal findings in any of the animals (n = 4/treatment) (data not
shown).
Discussion
CDDP is one of the most widely used chemotherapeutic agents for solid tumors; however,
its toxicity and chemotherapeutic tumor resistance severely limits its dose and use in many
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patients. Penetration of systemic CDDP into the lymphatics may be suboptimal, and
alternatives treatments for localized cancers, that is, surgical removal or radiation, can lead
to serious side effects such as lymphedema.14,15 Our objective in this study was to
determine if platinum therapy delivered to the loco-regional tissues and lymphatics, using a
FDA-approved biocompatible carrier, can increase drug exposure in the most tissues prone
to toxicity and decrease renal toxicity compared to traditional i.v. therapy with CDDP. A
delivery system for CDDP with reduced toxicity and ability to be administered through
intralymphatic routes would have important implications in the treatment of many CDDP
responsive cancers, for example, breast, nonsmall cell lung, ovarian, and head and neck
squamous cell carcinoma, as the lymphatics are involved in early-to-late diseases.
Numerous targeting and carrier strategies have been reported to increase the dosage of
CDDP reaching tumor-bearing tissues, while sparing normal tissues from toxic doses. These
technologies can be categorized into untargeted or passively targeted carriers and actively
targeted carriers, for example, antibodies. Among the untargeted carriers, polymeric micelle
formulations, that is, NC-6004, have demonstrated reduced nonspecific toxicities in
preclinical studies and have progressed to early clinical trials.16 In phase I trials, an
untargeted linear polymer conjugate of N-(2-hydroxypropyl)methacrylamide (HMPA) and
platinum, AP5280, had demonstrated higher sustained plasma concentrations of platinum in
humans with minimum toxicity compared to i.v. CDDP.17 These untargeted carriers rely on
the enhanced permeability and retention effect (EPR) to improve tumor accumulation of the
drug,18 but in tumors that are not highly vascularized, the EPR effect is greatly reduced and
untargeted carriers have less advantages.19 We sought to improve treatment of tumors,
regardless of tumor vascularity, by selectively confining treatment to the loco-regional
lymphatics of the tumor via a subcutaneous injection at the site where the primary tumor
would exist, allowing the drug to be delivered along the lymphatic pathway where tumors
are most likely to initially metastasize.
HA is a natural polysaccharide, of alternating D-glucuronic acid and N-acetyl D-glucosamine,
found endogenously in the extracellular matrix of connective tissues. HA is also a ligand for
CD44 receptor and is cleared primarily by the lymphatic system where it is catabolized in
the nodes by CD44 receptor-mediated endocytosis followed by lysosomal degradation.
Coupled with rapid uptake and a short half-life of 12–72 h,20 HA was seen as an ideal
carrier for the treatment of lymphatic tumors. HA has a known safety profile unlike other
possible carriers such as polyamino acids.21 Each disaccharide unit of HA contains a
carboxylic acid, facilitating coupling of CDDP.10–12 In a previous report, we first activated
the HA with silver nitrate prior to conjugation with CDDP, as this has been reported to
improve conjugation efficiency.12 However, we found it extremely difficult to remove all
traces of silver from the resulting conjugates, even after multiple rounds of extended dialysis
against water. In our initial pharmacokinetic and toxicity studies, a significant number of
animals succumbed to silver-induced toxicity as determined by pathological examination.
This led us to change our formulation scheme to eliminate silver from the conjugation
procedure and reoptimize the reaction for highest conjugation efficiency, which ultimately
did not impair formation of the HA–Pt conjugates. This is a significant advancement in
terms of clinical development as CDDP and HA are both approved by the FDA for use in
humans and no additional substances are required for formation of the complex. The
resulting complexes still had excellent antiproliferation activity against multiple breast
cancer lines in vitro, indicating the change in formulation method does not affect cell-based
drug efficacy.
The pharmacokinetics of s.c. HA–Pt was greatly altered compared to the same carrier
administered i.v. or the standard i.v. CDDP formulation. The greatly increased AUC of s.c.
HA–Pt is consistent with sustained release of platinum by the carrier. This effect may be due
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both to the delayed diffusion of platinum from the s.c. injection site and the slow release of
conjugated platinum from the carrier as i.v. administration of HA–Pt also resulted in
relatively large AUC. In a previous study, we determined that CDDP administered s.c. gives
rise to a comparable AUC, although this known vesicant can be highly inflammatory to
tissues, which may alter the diffusion rate. The relatively small Vss and Cl and large AUC of
i.v. HA–Pt indicates platinum release from the carrier may be slow. CDDP is readily
eliminated renally but the highly molecular weight of HA–Pt precludes rapid renal
clearance. Pharmacokinetic modeling suggests the carrier also slowed the rate constant of
distribution transfer of platinum from the plasma compartment to the tissues, which was
approximately 10-fold slower for i.v. HA–Pt compared to i.v. CDDP. This was possible due
to the ionization state and high molecular weight of HA, which is naturally cleared from the
body by lymphatic transport into the systemic circulation followed by enzymatic
degradation in the liver. CDDP administered s.c. did not significantly improve node
concentrations, giving slightly lower exposure than i.v. CDDP. Indeed, the majority of
CDDP administered s.c. was retained in the surrounding muscle tissue. Since CDDP is a
known vesicant, subcutaneous administration is not a safe and feasible method in the
absence of a drug carrier such as the HA conjugate we have described.
Clinical studies have indicated that CDDP's severe dose-limiting side effects are likely due
to the high peak plasma levels (Cmax) experienced immediately after i.v. administration.
Recent applications of metronomic dosing regimens have been shown to decrease toxicity
although they are clinically cumbersome and inconvenient and resulted in increased costs to
patients.6,7 Based on our preliminary experience with this delivery system, locally
administered carrier chemotherapeutics may avoid high peak concentrations due to slow
release of platinum from the carrier, with a half-life in saline of around 11 h compared to 4 h
for the standard CDDP formulation,9 and also as a result of slow platinum diffusion from the
tissues or lymph into the systemic circulation after release from the carrier.
We expected lymphatic delivery of platinum would reduce systemic tissue exposure
compared to i.v. CDDP, but s.c. HA–Pt had a much greater AUC than i.v. CDDP in most
tissues including the kidneys (Tab. 3). Vd is affected by partition coefficient and tissue and
plasma protein binding which may be different between the parent CDDP and our conjugate
HA–Pt. However, the urine creatinine studies did not indicate an increase in toxicity. The
reduction in toxicity could be due to protection of tissues by the carrier; HA frequently is
used in the clinic as a rescue therapy after accidental venipuncture by intravenous lines. The
predominant chemical form of platinum in the kidneys may differ significantly between the
two formulations as AAS measures only total elemental platinum, so it is unknown if
platinum from HA–Pt was detoxified before renal uptake. This could provide an explanation
as why the higher accumulated AUC in the kidney seen with HA–Pt was not as destructive
as i.v. CDDP. CDDP is believed to become nephrotoxic after displacement of a single
chloride leads to conjugation of the positively charged aqua ligand and glutathione, followed
by a series of metabolic reactions leading to cysteine conjugates that can produce highly
reactive thiol species in the proximal tubule cells.22 Since the mechanism of platinum
release and metabolism from HA is still under investigation, it is unknown if platinum
reaching the kidneys from HA–Pt complexes is significantly detoxified unlike the free drug
in i.v. CDDP. On-going studies are examining the distribution of carrier-bound and free
platinum at the cellular level in the tissues and tumors of xenografts by transmission electron
microscopy.
The increased tissue concentrations of platinum achieved with s.c. HA–Pt compared to i.v.
CDDP carries two potential advantages: (1) this could result in a lower dose of platinum
being required to achieve the same tissue effect such that the HA–Pt dose may be reduced
by several fold and still maintain equivalent tissue levels; and (2) maintaining therapeutic
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systemic concentrations of drug is important for utilizing this drug as an adjuvant therapy
since it is well known that most patients with cancers which have metastasized to the loco-
regional lymph nodes likely have micro in addition to systemic macrometastases. Therefore,
this treatment if extendable to the clinical situation could potentially replace daily systemic
intravenous therapy utilizing a less invasive and less-frequent dosing schedule, for example,
weekly subcutaneous dosing as compared to current therapy which is daily intravenous
infusion, while simultaneously providing augmented local drug delivery and exposure over
time to the loco-regional tumor basin and lymphatics. The larger tissue AUC of s.c. HA–Pt
may also increase rates of tumor apoptosis since a recent study found that a prolonged
subtoxic level of CDDP can substantial improve tumor cell apoptosis compared to a single
high dose.23 Overall, assuming linear pharmacokinetics, the total platinum dose for local
HA–Pt therapy could be reduced by 75% while maintaining the same systemic and node
concentrations of platinum as i.v. CDDP, possibly with lower concentrations in the other
tissues with the exception of the heart.
Conclusion
We have synthesized a conjugate of HA and CDDP that concentrates platinum in the breast
lymphatics after subcutaneous injection into the mammary fat pad with excellent
tolerability. These conjugates increased the plasma and tissue AUC of platinum and
increased the mean residence time and terminal elimination half-life. No injection site or
lymph node toxicities were observed; neither were any systemic toxicities observed in the
kidneys or brain on pathological examination. Ongoing xenograft studies are examining
HA–Pt conjugate efficacy in locally aggressive metastatic cancers, including xenograft
tumor models of breast cancer and head and neck squamous cell carcinomas. We believe
this intralymphatic delivery platform may offer significant advantages for the use of
platinum medicines in the management of locally advanced cancers, treating microscopic
lymph node disease with better efficacy than current high-dose systemic chemotherapy
without additional toxicities.
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AUC area under the curve
CDDP cis-diamminedichloroplatinum(II) or cisplatin
Cmax peak measured concentration of drug
HA hyaluronan
HA–Pt hyaluronan–CDDP conjugate
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TEM image of HA-Pt conjugates.
Cai et al. Page 11














In vitro release of CDDP from HA-Pt conjugate. Experiments were conducted in both water
(black) and PBS (grey).
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Plasma concentration of Pt after i.v. or s.c. injection of CDDP or HA-Pt (3.3 mg/kg Pt-basis)
(top). Concentration of Pt in ipsilateral (right) and axillary nodes and contralateral (left)
axillary nodes after i.v. or s.c. injection of CDDP or s.c. injection of HA-Pt conjugates (3.3
mg/kg Pt-basis) into the right mammary fatpad.
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Urine creatinine concentration of animals that received 3.3 mg/kg s.c. HA-Pt with or without
silver or i.v. CDDP. Student t-test analysis revealed urine creatinine level for study groups,
i.v. CDDP and s.c. HA-Pt without silver, differed significantly at day 22 and 30, and urine
creatinine level for study groups, s.c. HA-Pt with and without silver, differed significantly at
day 4, 6 and 7 (n = 5, p < 0.05).
Cai et al. Page 14

























Cai et al. Page 15
Table 1
IC50 Values of CDDP and HA–Pt in Human Cancer Cells
Cell Lines/IC50, μg/mL (μM) CDDP HA–Pt
MDA-MB-468LN 5.0 μg/mL (17 μM) 10 μg/mL (33 μM)
MDA-MB-231 6.0 μg/mL (20 μM) 10 μg/mL (33 μM)
MCF-7 6.0 μg/mL (20 μM) 11 μg/mL (37 μM)
JMAR 2.0 μg/mL (6.8 μM) 1.9 μg/mL (6.3 μM)
MDA-1986 2.4 μg/mL (8.1 μM) 1.9 μg/mL (6.2 μM)
Doses are given on a relative Pt basis and cells were exposed to drugs for 72 h followed by the resazurin blue assay for cell proliferation (n = 12
wells × 3 assays).
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